A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients With Selected Advanced Solid Tumors
What is the purpose of this trial?
The primary objectives of this study are to identify the recommended dose for expansion (RDE) (and recommended schedule) and/or maximum tolerated dose (MTD), and to characterize the safety and the tolerability of ADCT-901.
- Trial withADC Therapeutics SA
- Start Date06/14/2022
- End Date04/06/2024
- Last Updated06/15/2022
- Study HIC#2000030807